^
Association details:
Biomarker:CD44 expression
Cancer:Gastric Cancer
Drug:Herceptin (trastuzumab) (HER2 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer

Published date:
07/07/2020
Excerpt:
We observed ARPP-19 was up-regulated in Herceptin resistance gastric cancer cells NCI-N87-HR and MKN45-HR. The forced expression of ARPP-19 promoted, whereas the silencing of ARPP-19 impaired Herceptin resistance of HER2-positive gastric cancer cells both in vitro and in vivo. Moreover, ARPP-19 significantly enhanced the sphere formation capacity and CD44 expression, CD44 was also a positive factor of Herceptin resistance in HER2-positive gastric cancer cells.
DOI:
https://doi.org/10.2147/OTT.S253841